VerifiedRx

Built to Last: Rx for Resilience

We all know that clinician burnout negatively impacts the quality of patient care. That's why pharmacy residency accrediting bodies now emphasize resident well-being and professional sustainability as core components of residency training earlier in clinician careers. The American Society of Health-System Pharmacists (ASHP) Accreditation Standards for PGY1 and PGY2 Pharmacy Residencies include a formal requirement for programs to address resilience, well-being, and burnout prevention, reflecting the increasing recognition of burnout in healthcare. Joining us to talk that out are Tony Huke, Senior Pharmacy Executive Director with Vizient Pharmacy Advisory Solutions and Kendra Gage, Inpatient Clinical Pharmacist and the PGY 1 Residency Program Director at UCHealth, University of Colorado Hospital in Aurora, Colorado.
 
Guest speakers: 
Tony Huke, PharmD, BCPS, FASHP
Senior Pharmacy Executive Director
Vizient Pharmacy Advisory Solutions
 
Kendra Gage, PharmD, BCPS
Inpatient Clinical Pharmacist
PGY1 Pharmacy Residency Program Director
UCHealth
 
Host: 
Kerry Schwarz, PharmD, MPH 
Senior Clinical Manager, Evidence-Based Medicine and Outcomes
Center for Pharmacy Practice Excellence (CPPE)
 
Show Notes: 
[01:11-03:25] What’s new at the national level in terms of pharmacy resident resiliency and well-being
[03:26-03:56] The intentionality of well-being in pharmacy residency programs
[03:57-05:12] Examples from Kendra’s program
[05:13-06:40]  Program expectations to address resilience
[06:41-08:33]  Assessment and potential metrics of resiliency programs
[08:34-11:06]  The role of pharmacy leadership and residency program directors in resiliency
[11:07-12:34] Impact of resiliency programs so far
 
Links | Resources:
Accreditation Standards for PGY1 and PGY2 Pharmacy Residencies
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

COVID Vaccine Realities for 2025–26

Information on COVID vaccines is moving fast. On May 27th, HHS Secretary Robert F. Kennedy Jr. announced that COVID vaccines will no longer be universally recommended for healthy children or healthy pregnant women. That's a big shift, and understandably, it's raised a lot of questions. We're going to cut through the noise and take a look at where things really stand, who's getting vaccinated, how current guidance is evolving, and what this means for both children and adults as we look ahead to the next respiratory season.  Joining us to help sort it all out is Dr. John Schoen, Senior Clinical Manager of Drug Information at Vizient.
 
Guest speakers: 
John Schoen, PharmD, BCPS 
Senior Clinical Manager of Drug Information  
Vizient Center for Pharmacy Practice Excellence 
 
Host: 
Stacy Lauderdale, PharmD, BCPS 
Associate Vice President
Vizient Center for Pharmacy Practice Excellence 
 
Show Notes: 
[01:38-05:32] What changed in the recent CDC update for healthy children
[05:33-09:32] Discussion of COVID-19 outcomes and vaccination in children
[09:33-11:47] Specific risk factors for pediatric patients
[11:48-12:47] Is the US an outlier for not universally recommending the COVID-19 vaccine for healthy children and making no recommendation in healthy pregnant women?
[12:48-14:03] The FDA’s proposed regulatory framework for COVID-19 vaccine approval
[14:04-15:18] FDA’s approach to implementing revised requirements for randomized controlled trials
[15:19-16:57] Key discussion points from the May meeting of the Vaccines and Related Biological Products Advisory Committee
[17:00-18:27] Topics requiring further clarification about COVID-19 vaccine
 
Links | Resources:
Vizient resources:
Minute Market Insight: Potential ACIP COVID-19 recommendation changes April 2025: https://www.vizientinc.com/download?342668
Minute Market Insight: May 2025 COVID-19 vaccine recommendation and policy updates: https://www.vizientinc.com/download?352336
Additional resources:
FDA perspective piece published in NEJM: https://www.nejm.org/doi/full/10.1056/NEJMsb2506929
ACIP meeting information: https://www.cdc.gov/acip/meetings/index.html
CDC childhood immunization schedule: https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
CDC adult immunization schedule by medical condition: https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html
CDC RESP-NET: https://www.cdc.gov/resp-net/dashboard/
WHO COVID-19 dashboard: https://data.who.int/dashboards/covid19/deaths
MMWR - COVID-19–Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months: https://www.cdc.gov/mmwr/volumes/73/wr/mm7338a1.htm?utm_source=chatgpt.com
MMWR – MIS-C, US 2023: https://www.cdc.gov/mmwr/volumes/73/wr/mm7310a2.htm
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

Reverse Distribution needs your attention

Pharmacy reverse distributors play a key role in making pharmaceutical returns more efficient, helping with processing, financial settlements and delivering helpful data. They're in a unique spot to support efforts to prevent diversion, speed up inventory returns, and even contribute to sustainability goals. Kyle Hoelting, director of pharmacy supply assurance and stewardship at Vizient, along with Paige Ivey, senior national accounts director, and Houston Blankinship, senior director of customer experience for healthcare product operations at Inmar Intelligence join host Carolyn Liptak, pharmacy executive director in Vizient Center for Pharmacy Practice Excellence and host for today's conversation.
 
Guest speakers: 
Kyle Hoelting, Pharm.D, BCPS Director, Pharmacy Supply Assurance & StewardshipVizient Center for Pharmacy Practice Excellence
 
Paige IveySenior National Accounts DirectorInmar Intelligence
 
Houston BlankenshipSenior Director of Customer Experience for Healthcare Product OperationsInmar Intelligence
 
Host: Carolyn Liptak, MBA, RPh Pharmacy Executive Director Vizient
 
Show Notes: 
[01:05-03:33] Background for Kyle, Paige, Houston[03:34-05:10] How the pharmaceutical supply chain works and how everything is interconnected[05:10-09:32] How reverse distribution specifically supports pharmacy operations[09:33-11:16] How data that comes from reverse distribution can offer some great insights for pharmacy leaders[11:58-13:57] How data that comes from reverse distribution can give insight to drug shortages[13:58-16:42] Inmar's role with insight into drug shortages[16:43-21:05] Go-to resources for those wanting to explore more on stewardship and protective purchases
 
Links | Resources:
Drug shortage stewardship: A novel solution for an old problem
Vizient Essential Medications List
Vizient Key performance indicators for the management of drug shortages
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

NaV-igating pain - channeling suzetrigine

Recently, there has been a lot of interest generated by a new FDA approval. Suzetrigine (Journavx) was recently approved by the US Food and Drug Administration for the management of pain. Although there is a lot of excitement about having a new tool in the toolbox, there are certain limitations that are important to consider. In this episode of Verified Rx, Dave Peterson, pharmacist and drug information specialist for the University of Utah Health joins us to discuss this exciting new non opioid medication.
 
Guest speaker: 
Dave Peterson, PharmD, BCPS
Drug Information Specialist
University of Utah Drug Information Service
 
Host: 
Kerry Schwarz, PharmD, MPH
Senior Clinical Manager, Evidence-Based Medicine and Outcomes
Center for Pharmacy Practice Excellence (CPPE)
 
Show Notes: 
[00:54-02:24] Information about Suzetrigine
[02:25-04:06] What distinguishes suzetrigine from other non-opioid analgesics
[04:07-05:09] What suzetrigine is indicated for
[05:10-06:14] How suzetrigine is being studied
[06:15-08:40] Surgical models and the endpoints that we commonly see in these studies
[08:41-10:25] Making sense of discordant study results
[10:26-12:02] Moving beyond the evidence to real world utilization of suzetrigine
[12:03-14:03] How cost factors into real-world utilization
[14:04-16:21] What Dave is keeping his eye on in terms of clinical concerns
[16:22-17:28] What Dave is excited about with the advent of suzetrigine
 
Links | Resources:
No pain, much gain?
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

From Scale to Spend: The GLP-1 Surge

Traditional drug spending in the U.S. has surpassed specialty drug spending, and the primary force behind this trend is GLP-1 receptor agonists. These incretin-based therapies are transforming both the clinical and economic landscapes, from diabetes to obesity.
In this episode of the Center for Pharmacy Practice Excellence’s VerifiedRx podcast, host Tori Richie, Senior Consulting Director of Intelligence at Sg2 is joined by Vizient colleagues Stacy Lauderdale, AVP of Evidence-Based Medicine, Heather Pace, Senior Clinical Manager of Ambulatory Care, and Emily Fitt, Intelligence Consultant at Sg2. They delve into a comprehensive discussion on GLP-1s, covering topics from telehealth services and patient management strategies to the unique attributes that set these therapies apart.
Grab your coffee and get comfortable. This isn’t just a conversation; it’s a front-row seat to how GLP-1s are reshaping the future of obesity management.
 
Guest speakers: 
Stacy Lauderdale, Pharm.D, BCPS
Associate Vice President
Vizient Center for Pharmacy Practice Excellence
VerifiedRx Host
 
Heather Pace, Pharm.D
Sr. Clinical Manager of Ambulatory Care,
Vizient Center for Pharmacy Practice Excellence
 
Emily Fitt, MHA, MPH
Consultant
Sg2
 
Host: 
Tori Richie
Senior Consulting Director, Intelligence
Sg2
Sg2 Perspectives Host
 
Show Notes: 
[02:24-04:50] How GLP-1 medications differ from traditional treatments and shift from use in diabetes to obesity management
[04:51-05:54] The most common side effects of GLP-1 therapies and how clinicians can effectively manage patients
[05:55-08:49] Treatment teams for obesity management and the role of the pharmacist in the management of GLP-1 medications
[08:50-10:51] Challenges providers face integrating GLP-1 medications into practice
[10:16-13:20] Quality or outcome concerns with individuals who receive GLP-1 medications from telehealth providers
[13:21-15:01] Trends shaping this landscape
[15:02-21:14] Best practices that providers should deploy
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

Rash decisions - The current measles outbreak in the US

Widespread vaccination efforts declared measles eliminated in the United States in 2000. However, recent outbreaks have reignited public health concerns. The country is experiencing a growing number of measles cases with clusters reported in several states. A highly contagious virus, measles, poses serious risks, especially to unvaccinated individuals and vulnerable patient populations. Dr. John Schoen, Senior Clinical Manager of Drug Information at the Vizient Center for Pharmacy Practice Excellence, discusses the current outbreak, measles vaccine strategies, and answers questions about prevention and public health impact with Stacy Lauderdale, Associate Vice President at the Vizient Center for Pharmacy Practice Excellence and your VerifiedRx program host.
 
Guest speakers: 
John Schoen, Pharm.D, BCPS
Senior Clinical Manager of Drug Information
Vizient Center for Pharmacy Practice Excellence
 
Host: 
Stacy Lauderdale, Pharm.D, BCPS
Associate Vice President
Vizient Center for Pharmacy Practice Excellence
 
Show Notes: 
[01:12-03:30] Are we in an unprecedented situation in the United States?
[03:31-05:49] A brief overview about measles
[05:50-08:03] Overview of the MMR vaccine
[08:04-10:15] MMR vaccination rate in the United States
[10:16-12:27] Is there a link between autism and MMR vaccine
[12:28-14:47] Does the MMR vaccine cause measles?
[14:48-18:04] 1 vs. 2 doses of the MMR vaccine in adults
[18:05-21:25] Measles postexposure prophylaxis
[21:26-23:40] Vitamin A and measles
 
Links | Resources: 
Vizient Resources
Evidence Bites: 2025 Measles Outbreak
Resources
Measles cases and outbreaks: https://www.cdc.gov/measles/data-research/index.html
2013 MMWR measles recommendations: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm#Tab3
CDC measles vaccine recommendations: https://www.cdc.gov/measles/hcp/vaccine-considerations/index.html#cdc_generic_section_5-post-exposure-prophylaxis-for-measles
HAN alert 2025 outbreak: https://www.cdc.gov/han/2025/han00522.html
American Academy of Pediatrics recommendations: https://publications.aap.org/redbook/book/755/chapter/14079321/Measles?autologincheck=redirected
Information about the MMR vaccines: https://www.cdc.gov/vaccines/vpd/mmr/hcp/about.htm
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

Reversal Revisited: Agents for the Management of Factor Xa Inhibitor-Associated Bleeding

Prothrombin complex concentrates (PCCs) are frequently used off label for the management of factor Xa inhibitor-associated major bleeding.
In 2018, accelerated approval was granted for andexanet alfa, a specific factor Xa inhibitor reversal agent, for reversal of apixaban and rivaroxaban in the setting of life-threatening or uncontrolled bleeding.
Following accelerated approval, some clinical practice guidelines were updated to include recommendations for andexanet alfa preferentially over PCCs for reversal of life-threatening or uncontrolled bleeding due to rivaroxaban or apixaban. Other guidelines stated no preference of andexanet alfa over PCC.
In 2020, Vizient convened an expert panel to critically appraise the literature and provide consensus-based, expert opinions on the utilization of pharmacological reversal agents for factor Xa-related major bleeding. Since then, the body of literature evaluating these agents has expanded to include a randomized controlled trial, ANNEXa-I, the results of which were submitted to the US Food and Drug Administration to convert the approval of andexanet alfa from accelerated to full approval.
Dr. Lisa Baumann-Kreuziger, Associate Professor of Hematology and Oncology, Medical College of Wisconsin and medical director of the Antithrombotic Therapy Management Program at Froedtert Health discusses the current status of management of factor Xa inhibitor-associated major bleeding with Dr. Kerry Schwarz, Senior Clinical Manager of Evidence-Based Medicine and Outcomes with the Vizient Center for Pharmacy Practice Excellence, and your program host.
 
Guest speakers: Liza Baumann-Kreuziger, MD, MSInvestigator, Blood Research Institute, Versiti Associate Professor of Hematology and Oncology, Medical College of WisconsinMedical Director, Antithrombotic Therapy Management Program at Froedtert Health
 
Host: Kerry Schwarz, Pharm.D, MPHSenior Clinical Manager of Evidence-Based Medicine and Outcomes Vizient Center for Pharmacy Practice Excellence
 
Show Notes:
[02:25-04:26] The current state of hemostatic management in the setting of factor Xa inhibitor-related major bleeding
[04:27- 05:35] Limitations of available evidence making clinical practice and formulary decision making so challenging
[05:35 – 10:52] Publication of the first randomized controlled trial, ANNEXa-I, comparing andexanet alfa to usual care
[10:52-14:49] Meeting of the FDA advisory committee and subsequent complete response letter
[14:50-16:45] How we can approach clinical management of patients and formulary decision-making in the current state
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

Dose of data: Drug shortage KPIs

Drug shortages continue to pose significant challenges for hospitals and health systems. While they gained national attention during the COVID-19 pandemic, pharmacy departments have managed them for decades. During high-profile shortages, institutions must rapidly establish command centers, engage stakeholders, and implement plans for frontline staff. Once resolved, shortages often recede from immediate focus until the next crisis emerges. However, pharmacy departments consistently manage shortages on a daily basis, often without recognition.
Dr. Kyle Hoelting, Sr. Clinical Manager of Drug Information and Drug Shortages at Vizient, Dr. Heather Warhurst, Director of Drug Use Policy, Quality Initiative and Regulatory at IU Health, and Dr. Chris Nagy, Medication Sourcing and Supply Pharmacist at Intermountain Health join us to discuss a Vizient workgroup project designed to measure the impact of drug shortages and highlight the crucial role of pharmacists in their management.
 
Guest speakers: 
Heather Warhurst, Pharm.D, MHA
Director of Drug Use Policy, Quality Initiative and Regulatory
IU Health
 
Chris Nagy, Pharm.D, BCPS
Medication Sourcing and Supply Pharmacist
Intermountain Health
 
Kyle Holting, Pharm.D, BCPS
Senior Clinical Manager of Drug Information
Vizient Center for Pharmacy Practice Excellence
 
Host:
Stacy Lauderdale, Pharm.D, BCPS
Associate Vice President
Vizient Center for Pharmacy Practice Excellence
 
Show Notes: 
[01:18-02:29] Heather and Chris introductions
[02:30-04:00] Vizient drug shortage key performance indicators (KPI) workgroup series
[04:01-10:04] Labor and Inventory drug shortage KPIs
[07:50-16:56] Patient Safety and Stress to Front Line Staff drug shortage KPIs
[16:57-18:32] Call to Action
 
Links | Resources: 
Key performance indicators for the management of drug shortages
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

What's pneu part 3: pneumococcal vaccines update

The widespread use of pneumococcal conjugate vaccine (PCV) in children has dramatically lowered the incidence of pneumococcal disease through direct and indirect effects. Despite this progress, pneumococcal pneumonia still leads to more than 200,000 adult hospitalizations annually in the United States. Older adults, individuals with underlying health conditions, and certain racial groups continue to experience higher rates of pneumococcal disease. Dr. John Schoen, Senior Clinical Manager of Drug Information at the Vizient Center for Pharmacy Practice Excellence, joins Program Host Stacy Lauderdale to discuss the newest adult pneumococcal vaccine, PCV21, and recent updates to age-based pneumococcal vaccine recommendations.
 
Guest speakers: 
John Schoen, Pharm.D, BCPS
Senior Clinical Manager of Drug Information
Vizient Center for Pharmacy Practice Excellence
 
Host: 
Stacy Lauderdale, Pharm.D, BCPS
Associate Vice President
Vizient Center for Pharmacy Practice Excellence
 
Show Notes: 
[01:25-02:53] Background on PCV21
[02:54-07:56] Difference between PCV20 and PCV21
[07:57-16:15] Discussing the new ACIP recommendation to move the universal age for pneumococcal vaccination from 65 years of age down to 50 years of age and older
[08:31-16:15] Why a healthy 50-year-old who has no risk factors for invasive pneumococcal disease should get a pneumococcal vaccination
[16:16-17:57] Summary of other changes in the most recent MMWR
[17:58-19:34] What organizations consider when selecting specific pneumococcal vaccines
[19:35-21:18] What’s in the pipeline for  pneumococcal vaccines
 
Links | Resources: 
Publicly available resources
Previous VerifiedRx podcasts on pneumococcal vaccines:
What’s pneu with pneumococcal vaccines? – March 29, 2022
What’s pneu part 2: pneumococcal vaccines update – February 13, 2024
January 2024 MMWR - ACIP recommendations for the use of PCV in adults ≥ 50 years of age
Vizient client exclusive resources
2025 pneumococcal vaccines side-by-side comparison
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed

No pain, much gain?

Prescription opioids continue to be the most frequently misused prescription drugs in the United States, having caused nearly 300,000 deaths over the past two decades. Signed into law in 2022, the No Pain Act expands Medicare reimbursement for specific non-opioid pain management options. Carolyn Liptak, Pharmacy Executive Director in the Vizient Center for Pharmacy Practice Excellence, and Dr. Phil Mentler, Senior Consulting Director at Vizient join Program Host Stacy Lauderdale to discuss the implications of the No Pain Act, which took effect on January 1, 2025.
 
Guest speakers: 
Carolyn Liptak, MBA, RPh
Pharmacy Executive Director
Vizient
 
Phillipe Mentler, Pharm.D, BCPS
Senior Consulting Director
Vizient
 
Host: 
Stacy Lauderdale, Pharm.D, BCPS
Associate Vice President
Vizient
  
Show Notes: 
[01:49-03:48] Background on the No Pain Act
[03:49-05:03] What is new as of January 1, 2025
[05:04-05:37] The difference between a hospital outpatient department versus an ambulatory surgical center
[05:38-06:30] Other drugs and or devices that are on the list other than Exparel
[06:31-07:42] What specifically prevents multi modal drugs and therapy from being added to the list
[07:43-08:24] Specific language that needs to be included in the FDA labeling for non-opioids to be considered for reimbursement under the Act
[08:25-10:50] Reimbursement basics of the NO PAIN Act
[14:32-15:44] Reimbursement
[15:45-17:04] The importance of opioids in pain management
 
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Spotify
Android
RSS Feed